Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 186

recruiting
3 982
countries
28
conditions
2 106

3 667 trials match your criteria

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Study on Electrochemotherapy with Bleomycin and Cisplatin for Treating Vulvar Paget's Disease and Precancerous Lesions in Newly Diagnosed or Recurrent Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin

Ovarian cancer

Not recruiting

Study on Doxorubicin Hydrochloride and Trabectedin for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trabectedin

Cardiac amyloidosis

Not recruiting

Study on the Use of Flutemetamol (18F) for Diagnosing Cardiac Amyloidosis in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Flutemetamol (18F)

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Frexalimab

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept

Cardiac amyloidosis

Not recruiting

Study of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Type 2 diabetes mellitus+2

Not recruiting

Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Study on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.